Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study

BACKGROUND: The efficacy of antiviral drugs that neutralize antibody drugs and fight against SARS-COV-2 is reported to be attenuated by genetic mutations of the virus in vitro. When B-cell immunocompromised patients are infected with SARS-COV-2, the infection can be prolonged, and genetic mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimazu, Haruka, Wada, Daiki, Maruyama, Shuhei, Inoue, Akira, Kashihara, Masami, Yoshihara, Tomoyuki, Saito, Fukuki, Yoshiya, Kazuhisa, Nakamori, Yasushi, Kuwagata, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636837/
https://www.ncbi.nlm.nih.gov/pubmed/37946111
http://dx.doi.org/10.1186/s12879-023-08797-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636837/
https://www.ncbi.nlm.nih.gov/pubmed/37946111
http://dx.doi.org/10.1186/s12879-023-08797-6

Ejemplares similares